179 related articles for article (PubMed ID: 16963452)
1. Selection and characterization of Her2 binding-designed ankyrin repeat proteins.
Zahnd C; Pecorari F; Straumann N; Wyler E; Plückthun A
J Biol Chem; 2006 Nov; 281(46):35167-75. PubMed ID: 16963452
[TBL] [Abstract][Full Text] [Related]
2. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.
Boersma YL; Chao G; Steiner D; Wittrup KD; Plückthun A
J Biol Chem; 2011 Dec; 286(48):41273-41285. PubMed ID: 21979953
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2.
Jost C; Schilling J; Tamaskovic R; Schwill M; Honegger A; Plückthun A
Structure; 2013 Nov; 21(11):1979-91. PubMed ID: 24095059
[TBL] [Abstract][Full Text] [Related]
4. DARPins: a new generation of protein therapeutics.
Stumpp MT; Binz HK; Amstutz P
Drug Discov Today; 2008 Aug; 13(15-16):695-701. PubMed ID: 18621567
[TBL] [Abstract][Full Text] [Related]
5. Structural model for the interaction of a designed Ankyrin Repeat Protein with the human epidermal growth factor receptor 2.
Epa VC; Dolezal O; Doughty L; Xiao X; Jost C; Plückthun A; Adams TE
PLoS One; 2013; 8(3):e59163. PubMed ID: 23527120
[TBL] [Abstract][Full Text] [Related]
6. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.
Merlin JL; Barberi-Heyob M; Bachmann N
Ann Oncol; 2002 Nov; 13(11):1743-8. PubMed ID: 12419746
[TBL] [Abstract][Full Text] [Related]
7. DARPins: a true alternative to antibodies.
Stumpp MT; Amstutz P
Curr Opin Drug Discov Devel; 2007 Mar; 10(2):153-9. PubMed ID: 17436550
[TBL] [Abstract][Full Text] [Related]
8. A designed ankyrin repeat protein evolved to picomolar affinity to Her2.
Zahnd C; Wyler E; Schwenk JM; Steiner D; Lawrence MC; McKern NM; Pecorari F; Ward CW; Joos TO; Plückthun A
J Mol Biol; 2007 Jun; 369(4):1015-28. PubMed ID: 17466328
[TBL] [Abstract][Full Text] [Related]
9. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.
Menendez JA; Vazquez-Martin A; Colomer R; Brunet J; Carrasco-Pancorbo A; Garcia-Villalba R; Fernandez-Gutierrez A; Segura-Carretero A
BMC Cancer; 2007 May; 7():80. PubMed ID: 17490486
[TBL] [Abstract][Full Text] [Related]
10. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
Arpino G; Gutierrez C; Weiss H; Rimawi M; Massarweh S; Bharwani L; De Placido S; Osborne CK; Schiff R
J Natl Cancer Inst; 2007 May; 99(9):694-705. PubMed ID: 17470737
[TBL] [Abstract][Full Text] [Related]
11. A rapid, site-selective and efficient route to the dual modification of DARPins.
Moody P; Chudasama V; Nathani RI; Maruani A; Martin S; Smith ME; Caddick S
Chem Commun (Camb); 2014 May; 50(38):4898-900. PubMed ID: 24687090
[TBL] [Abstract][Full Text] [Related]
12. Directed evolution of anti-HER2 DARPins by SNAP display reveals stability/function trade-offs in the selection process.
Houlihan G; Gatti-Lafranconi P; Lowe D; Hollfelder F
Protein Eng Des Sel; 2015 Sep; 28(9):269-79. PubMed ID: 26134501
[TBL] [Abstract][Full Text] [Related]
13. DARPins against a functional IgE epitope.
Baumann MJ; Eggel A; Amstutz P; Stadler BM; Vogel M
Immunol Lett; 2010 Oct; 133(2):78-84. PubMed ID: 20673836
[TBL] [Abstract][Full Text] [Related]
14. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
[TBL] [Abstract][Full Text] [Related]
15. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
16. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
[TBL] [Abstract][Full Text] [Related]
17. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
18. Biology of HER2 and its importance in breast cancer.
Yarden Y
Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
20. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display.
Steiner D; Forrer P; Plückthun A
J Mol Biol; 2008 Oct; 382(5):1211-27. PubMed ID: 18706916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
